JP2023510853A5 - - Google Patents
Info
- Publication number
- JP2023510853A5 JP2023510853A5 JP2022542739A JP2022542739A JP2023510853A5 JP 2023510853 A5 JP2023510853 A5 JP 2023510853A5 JP 2022542739 A JP2022542739 A JP 2022542739A JP 2022542739 A JP2022542739 A JP 2022542739A JP 2023510853 A5 JP2023510853 A5 JP 2023510853A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- expression vector
- individual
- use according
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960583P | 2020-01-13 | 2020-01-13 | |
| US62/960,583 | 2020-01-13 | ||
| US202063034868P | 2020-06-04 | 2020-06-04 | |
| US63/034,868 | 2020-06-04 | ||
| US202063061634P | 2020-08-05 | 2020-08-05 | |
| US63/061,634 | 2020-08-05 | ||
| PCT/US2021/013130 WO2021146213A1 (en) | 2020-01-13 | 2021-01-12 | Methods for treating cancers using gm-csf encoding polynucleotide and additional agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510853A JP2023510853A (ja) | 2023-03-15 |
| JP2023510853A5 true JP2023510853A5 (https=) | 2024-01-18 |
| JP7815124B2 JP7815124B2 (ja) | 2026-02-17 |
Family
ID=76857765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542739A Active JP7815124B2 (ja) | 2020-01-13 | 2021-01-12 | Ｇｍ－ｃｓｆをコードするポリヌクレオチドと追加薬剤を用いてがんを治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11400170B2 (https=) |
| EP (1) | EP4090380A1 (https=) |
| JP (1) | JP7815124B2 (https=) |
| CN (1) | CN115335085A (https=) |
| CA (1) | CA3158900A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4440704A2 (en) * | 2021-11-30 | 2024-10-09 | Gradalis, Inc. | Methods for treatment response to cancers |
| WO2025117756A1 (en) * | 2023-11-28 | 2025-06-05 | Gradalis, Inc. | Neoantigen immunotherapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916530B2 (en) | 2005-11-18 | 2014-12-23 | Gradalis, Inc. | Individualized cancer therapy |
| US8906874B2 (en) | 2006-11-09 | 2014-12-09 | Gradalis, Inc. | Bi-functional shRNA targeting Stathmin 1 and uses thereof |
| US8758998B2 (en) | 2006-11-09 | 2014-06-24 | Gradalis, Inc. | Construction of bifunctional short hairpin RNA |
| US8252526B2 (en) | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
| EP2217244A4 (en) * | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
| US8969068B2 (en) | 2008-04-30 | 2015-03-03 | Gradalis, Inc. | Processes for the preparation of highly pure plasmid compositions by enzymatic digestion of colanic acid |
| CA2772057C (en) | 2009-09-03 | 2016-02-02 | Strike Bio, Inc. | Targeted delivery using tissue-specific peptidomimetic ligands |
| KR101543350B1 (ko) | 2009-10-30 | 2015-08-11 | 베이롤 칼리지 오브 메드신 | Ｐｄｘ－１을 발현하는 신경내분비 종양에서 ｐｄｘ－１ 종양유전자를 표적화한 신규한 치료용 ｒｎａ 간섭 기법 |
| US9157084B2 (en) * | 2009-12-23 | 2015-10-13 | Gradalis, Inc. | Furin-knockdown bi-functional RNA |
| SG181880A1 (en) * | 2009-12-23 | 2012-07-30 | Gradalis Inc | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
-
2021
- 2021-01-12 CA CA3158900A patent/CA3158900A1/en active Pending
- 2021-01-12 EP EP21704094.8A patent/EP4090380A1/en active Pending
- 2021-01-12 JP JP2022542739A patent/JP7815124B2/ja active Active
- 2021-01-12 CN CN202180009173.8A patent/CN115335085A/zh active Pending
- 2021-01-25 US US17/157,790 patent/US11400170B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagasaka et al. | KRAS inhibitors–yes but what next? Direct targeting of KRAS–vaccines, adoptive T cell therapy and beyond | |
| Leowattana et al. | Systemic treatment for metastatic colorectal cancer | |
| Liontos et al. | Systemic therapy in cervical cancer: 30 years in review | |
| Tariq et al. | Biliary tract cancers: current knowledge, clinical candidates and future challenges | |
| Kim et al. | Personalized therapy on the horizon for squamous cell carcinoma of the lung | |
| Martini et al. | Present and future of metastatic colorectal cancer treatment: a review of new candidate targets | |
| Ku | Systemic therapy for esophageal cancer: chemotherapy | |
| Chong et al. | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets | |
| Goldstein et al. | New molecular and immunotherapeutic approaches in biliary cancer | |
| Qiu et al. | Prospects of immunotherapy for triple-negative breast cancer | |
| Lau et al. | Evolving treatment landscape for early and advanced pancreatic cancer | |
| Tong et al. | Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions | |
| JP2023510853A5 (https=) | ||
| Shitara et al. | Advances in systemic therapy for metastatic or advanced gastric cancer | |
| Serzan et al. | Drugs in development for small cell lung cancer | |
| Wu et al. | Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics: LW Wu et al. | |
| Wang et al. | Advances of DNA damage repair-related drugs and combination with immunotherapy in tumor treatment | |
| Ishii et al. | Dawn of precision medicine on gastric cancer | |
| Cardona et al. | Squamous cell lung cancer: genomic evolution and personalized therapy | |
| Singh et al. | Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies | |
| Duenas-Gonzalez et al. | Emerging drugs for cervical cancer | |
| Peng et al. | Emerging therapeutic approaches to pancreatic adenocarcinoma: advances and future directions | |
| Ho et al. | Cancer Management by Tyrosine Kinase Inhibitors: Efficacy | |
| Częścik et al. | Evolution or Revolution in Colorectal Cancer Treatment: Present and Future of New Therapeutic Options. A Narrative Review | |
| Oppel et al. | The potential of tumor debulking to support molecular targeted therapies |